Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial results buried in Merck’s 300-page 10-K can dictate the future of therapies like Keytruda, yet those details are easy to miss. Add patent-expiration tables, FDA correspondence, and worldwide vaccine sales data and you have one of the most complex disclosure packages in the market. That’s why professionals searching for Merck & Co. SEC filings explained simply come here first.
Stock Titan’s AI reads every Merck & Co. annual report 10-K simplified, Merck & Co. quarterly earnings report 10-Q filing, and Merck & Co. 8-K material events explained the moment they hit EDGAR. Our technology pinpoints where management discusses pipeline milestones, litigation reserves, or emerging biosimilar risks so you can act quickly instead of parsing footnotes.
- Get instant alerts on Merck & Co. Form 4 insider transactions real-time and spot trading patterns before key data releases.
- See concise takeaways from every Merck & Co. proxy statement executive compensation to understand how R&D targets drive bonuses.
- Dive into patent expiry schedules and regional vaccine sales in seconds with AI-generated tables.
Whether you’re monitoring Merck & Co. insider trading Form 4 transactions, comparing quarter-over-quarter oncology revenue, or simply understanding Merck & Co. SEC documents with AI, our platform delivers. Each document arrives with a plain-language summary, key-metric extraction, and cross-linking to prior periods for seamless Merck & Co. earnings report filing analysis. No more hunting through exhibits—just clean insights updated in real time.
Merck & Co., Inc. (MRK) � Form 4 insider transaction filing
Director Christine E. Seidman reported two minor changes to her beneficial ownership as of 30 June 2025:
- Non-derivative securities: a disposition of 100 shares of Merck common stock (transaction code and price not disclosed). Her post-transaction direct holding is shown as 100 shares.
- Derivative securities: acquisition of 102.6402 phantom stock units at a reference price of $79.16. Phantom stock is settled 1-for-1 in cash after the director leaves the board under Merck’s Deferred Payment of Directors� Compensation Plan. Total phantom units after the transaction stand at 18,495.8789.
No other equity awards, options, or material transactions were reported. Given Merck’s multibillion-dollar market capitalization, the size of these trades is immaterial and should not affect the company’s valuation or governance structure.
Deal overview. The Toronto-Dominion Bank (TD) plans to issue senior unsecured Contingent Income Auto-Callable Securities maturing 10 July 2026 that are linked to the common stock of Apple Inc. (AAPL).
Key economics. Investors pay US$1,000 per note and may receive a quarterly contingent coupon of US$28.55 (11.42% p.a.) on any determination date at which AAPL closes at or above 80% of its initial share price (the “downside threshold�). If on any of the first three determination dates AAPL closes at or above 100% of the initial share price (the “call threshold�), the notes are automatically redeemed for par plus the coupon. If not redeemed, principal is protected only when the final price is at or above the 80% threshold; otherwise holders suffer a 1-to-1 loss on the decline in AAPL, potentially forfeiting their entire investment.
Structural and credit considerations. � Tenor: ~12 months (pricing 7 Jul 2025, maturity 10 Jul 2026). � Estimated value: US$940-975 (94-97.5% of issue price) reflecting dealer margin and hedge costs. � Distribution fees total US$17.50 per note (1.75%). � TD is the sole calculation agent; all payments depend on TD’s credit as senior unsecured obligations of its Series H debt. � Notes will not list on an exchange; secondary liquidity, if any, will be provided on a best-efforts basis by TD affiliates and may be materially below par.
Risk/return profile. Investors trade equity upside and dividend participation for an above-market coupon that is contingent, limited upside (coupons only) and full downside exposure below the 80% barrier. Automatic redemption can shorten the holding period, creating reinvestment risk. In adverse scenarios—persistent AAPL weakness or a TD credit event—investors may earn no coupons and lose significant principal.
Target investor. Suitable only for investors who: 1) are comfortable with single-stock volatility, 2) can tolerate 100% capital loss, 3) desire potentially high income for one year, and 4) accept TD credit and liquidity risk.
Fortress Biotech, Inc. (Nasdaq: FBIO, preferred: FBIOP) filed a Form 8-K disclosing the voting results of its 17 June 2025 virtual annual meeting of stockholders.
- Director elections: All seven incumbent directors were re-elected with support levels ranging from 93.8% to 98.3% of votes cast, confirming board continuity.
- Auditor ratification: KPMG LLP was re-appointed with 20.4 million votes FOR (98.5%), 0.3 million AGAINST, and 15 k abstentions; brokers were permitted to vote, explaining the larger vote total.
- Say-on-Pay: Executive compensation received 9.39 million FOR (94.7%) versus 0.31 million AGAINST and 0.11 million abstentions; 10.92 million broker non-votes were recorded.
- Say-on-Pay frequency: Stockholders favored a three-year vote cycle (7.42 million votes) over one-year (2.05 million) or two-year (0.18 million) options. The board adopted the triennial schedule until the next required vote in 2031.
- Charter amendment (officer exculpation): Approved with 7.96 million FOR (80%), 1.72 million AGAINST, and 0.12 million abstentions; 10.92 million broker non-votes.
No financial performance data, capital raises, or strategic transactions were reported. The filing is primarily a routine governance update with limited immediate impact on valuation, although the adoption of officer exculpation and a triennial Say-on-Pay cycle slightly reduces direct shareholder oversight.